S&P 500   3,909.87 (+2.59%)
DOW   31,605.03 (+2.17%)
QQQ   323.54 (+2.99%)
AAPL   127.45 (+5.10%)
MSFT   237.17 (+2.06%)
FB   265.96 (+3.24%)
GOOGL   2,070.37 (+2.40%)
TSLA   714.13 (+5.72%)
AMZN   3,144.85 (+1.68%)
NVDA   549.38 (+0.15%)
BABA   241.73 (+1.67%)
CGC   34.69 (+5.92%)
GE   13.19 (+5.18%)
MU   94.61 (+3.37%)
NIO   49.75 (+8.67%)
AMD   86.28 (+2.09%)
T   28.15 (+0.93%)
F   12.03 (+2.82%)
ACB   11.11 (+5.61%)
DIS   195.24 (+3.28%)
BA   224.07 (+5.69%)
NFLX   550.81 (+2.22%)
BAC   35.97 (+3.63%)
S&P 500   3,909.87 (+2.59%)
DOW   31,605.03 (+2.17%)
QQQ   323.54 (+2.99%)
AAPL   127.45 (+5.10%)
MSFT   237.17 (+2.06%)
FB   265.96 (+3.24%)
GOOGL   2,070.37 (+2.40%)
TSLA   714.13 (+5.72%)
AMZN   3,144.85 (+1.68%)
NVDA   549.38 (+0.15%)
BABA   241.73 (+1.67%)
CGC   34.69 (+5.92%)
GE   13.19 (+5.18%)
MU   94.61 (+3.37%)
NIO   49.75 (+8.67%)
AMD   86.28 (+2.09%)
T   28.15 (+0.93%)
F   12.03 (+2.82%)
ACB   11.11 (+5.61%)
DIS   195.24 (+3.28%)
BA   224.07 (+5.69%)
NFLX   550.81 (+2.22%)
BAC   35.97 (+3.63%)
S&P 500   3,909.87 (+2.59%)
DOW   31,605.03 (+2.17%)
QQQ   323.54 (+2.99%)
AAPL   127.45 (+5.10%)
MSFT   237.17 (+2.06%)
FB   265.96 (+3.24%)
GOOGL   2,070.37 (+2.40%)
TSLA   714.13 (+5.72%)
AMZN   3,144.85 (+1.68%)
NVDA   549.38 (+0.15%)
BABA   241.73 (+1.67%)
CGC   34.69 (+5.92%)
GE   13.19 (+5.18%)
MU   94.61 (+3.37%)
NIO   49.75 (+8.67%)
AMD   86.28 (+2.09%)
T   28.15 (+0.93%)
F   12.03 (+2.82%)
ACB   11.11 (+5.61%)
DIS   195.24 (+3.28%)
BA   224.07 (+5.69%)
NFLX   550.81 (+2.22%)
BAC   35.97 (+3.63%)
S&P 500   3,909.87 (+2.59%)
DOW   31,605.03 (+2.17%)
QQQ   323.54 (+2.99%)
AAPL   127.45 (+5.10%)
MSFT   237.17 (+2.06%)
FB   265.96 (+3.24%)
GOOGL   2,070.37 (+2.40%)
TSLA   714.13 (+5.72%)
AMZN   3,144.85 (+1.68%)
NVDA   549.38 (+0.15%)
BABA   241.73 (+1.67%)
CGC   34.69 (+5.92%)
GE   13.19 (+5.18%)
MU   94.61 (+3.37%)
NIO   49.75 (+8.67%)
AMD   86.28 (+2.09%)
T   28.15 (+0.93%)
F   12.03 (+2.82%)
ACB   11.11 (+5.61%)
DIS   195.24 (+3.28%)
BA   224.07 (+5.69%)
NFLX   550.81 (+2.22%)
BAC   35.97 (+3.63%)
Log in
NASDAQ:NERV

Minerva Neurosciences Competitors

$3.15
+0.05 (+1.61 %)
(As of 03/1/2021 03:07 PM ET)
Add
Compare
Today's Range
$3.10
Now: $3.15
$3.20
50-Day Range
$2.56
MA: $3.22
$3.59
52-Week Range
$1.81
Now: $3.15
$15.22
Volume6,870 shs
Average Volume830,036 shs
Market Capitalization$134.42 million
P/E RatioN/A
Dividend YieldN/A
Beta1.49

Competitors

Minerva Neurosciences (NASDAQ:NERV) Vs. CLVS, ALT, AMYT, BYSI, MGTA, and NLTX

Should you be buying NERV stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Minerva Neurosciences, including Clovis Oncology (CLVS), Altimmune (ALT), Amryt Pharma (AMYT), BeyondSpring (BYSI), Magenta Therapeutics (MGTA), and Neoleukin Therapeutics (NLTX).

Minerva Neurosciences (NASDAQ:NERV) and Clovis Oncology (NASDAQ:CLVS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

Analyst Recommendations

This is a breakdown of current recommendations for Minerva Neurosciences and Clovis Oncology, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Minerva Neurosciences02302.60
Clovis Oncology22202.00

Minerva Neurosciences currently has a consensus price target of $6.75, suggesting a potential upside of 113.61%. Clovis Oncology has a consensus price target of $8.80, suggesting a potential upside of 41.71%. Given Minerva Neurosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Minerva Neurosciences is more favorable than Clovis Oncology.

Profitability

This table compares Minerva Neurosciences and Clovis Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Minerva NeurosciencesN/A-51.19%-29.75%
Clovis Oncology-230.34%N/A-57.56%

Risk & Volatility

Minerva Neurosciences has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500. Comparatively, Clovis Oncology has a beta of 2.1, indicating that its stock price is 110% more volatile than the S&P 500.

Institutional & Insider Ownership

66.3% of Minerva Neurosciences shares are held by institutional investors. Comparatively, 57.8% of Clovis Oncology shares are held by institutional investors. 12.0% of Minerva Neurosciences shares are held by company insiders. Comparatively, 6.6% of Clovis Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Minerva Neurosciences and Clovis Oncology's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Minerva NeurosciencesN/AN/A$-72,180,000.00($1.85)-1.70
Clovis Oncology$143.01 million3.85$-400,420,000.00($7.60)-0.82

Minerva Neurosciences has higher earnings, but lower revenue than Clovis Oncology. Minerva Neurosciences is trading at a lower price-to-earnings ratio than Clovis Oncology, indicating that it is currently the more affordable of the two stocks.

Summary

Minerva Neurosciences beats Clovis Oncology on 9 of the 13 factors compared between the two stocks.

Minerva Neurosciences (NASDAQ:NERV) and Altimmune (NASDAQ:ALT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

Earnings and Valuation

This table compares Minerva Neurosciences and Altimmune's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Minerva NeurosciencesN/AN/A$-72,180,000.00($1.85)-1.70
Altimmune$5.80 million94.71$-20,520,000.00($0.98)-16.95

Altimmune has higher revenue and earnings than Minerva Neurosciences. Altimmune is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

66.3% of Minerva Neurosciences shares are held by institutional investors. Comparatively, 66.2% of Altimmune shares are held by institutional investors. 12.0% of Minerva Neurosciences shares are held by company insiders. Comparatively, 2.7% of Altimmune shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for Minerva Neurosciences and Altimmune, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Minerva Neurosciences02302.60
Altimmune00603.00

Minerva Neurosciences currently has a consensus price target of $6.75, suggesting a potential upside of 113.61%. Altimmune has a consensus price target of $31.75, suggesting a potential upside of 91.50%. Given Minerva Neurosciences' higher possible upside, research analysts clearly believe Minerva Neurosciences is more favorable than Altimmune.

Risk & Volatility

Minerva Neurosciences has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500. Comparatively, Altimmune has a beta of 1.51, indicating that its stock price is 51% more volatile than the S&P 500.

Profitability

This table compares Minerva Neurosciences and Altimmune's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Minerva NeurosciencesN/A-51.19%-29.75%
Altimmune-659.33%-46.39%-38.32%

Summary

Altimmune beats Minerva Neurosciences on 7 of the 13 factors compared between the two stocks.

Minerva Neurosciences (NASDAQ:NERV) and Amryt Pharma (NASDAQ:AMYT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

Profitability

This table compares Minerva Neurosciences and Amryt Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Minerva NeurosciencesN/A-51.19%-29.75%
Amryt PharmaN/AN/AN/A

Analyst Ratings

This is a breakdown of current recommendations and price targets for Minerva Neurosciences and Amryt Pharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Minerva Neurosciences02302.60
Amryt Pharma01202.67

Minerva Neurosciences currently has a consensus price target of $6.75, suggesting a potential upside of 113.61%. Amryt Pharma has a consensus price target of $41.6667, suggesting a potential upside of 182.68%. Given Amryt Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Amryt Pharma is more favorable than Minerva Neurosciences.

Earnings & Valuation

This table compares Minerva Neurosciences and Amryt Pharma's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Minerva NeurosciencesN/AN/A$-72,180,000.00($1.85)-1.70
Amryt Pharma$58.12 million9.07$-30,753,600.00($0.86)-17.14

Amryt Pharma has higher revenue and earnings than Minerva Neurosciences. Amryt Pharma is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

66.3% of Minerva Neurosciences shares are held by institutional investors. Comparatively, 15.4% of Amryt Pharma shares are held by institutional investors. 12.0% of Minerva Neurosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Amryt Pharma beats Minerva Neurosciences on 7 of the 11 factors compared between the two stocks.

BeyondSpring (NASDAQ:BYSI) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

Valuation & Earnings

This table compares BeyondSpring and Minerva Neurosciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BeyondSpringN/AN/A$-38,080,000.00($1.55)-8.54
Minerva NeurosciencesN/AN/A$-72,180,000.00($1.85)-1.70

BeyondSpring is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares BeyondSpring and Minerva Neurosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BeyondSpringN/A-221.67%-139.97%
Minerva NeurosciencesN/A-51.19%-29.75%

Institutional & Insider Ownership

7.1% of BeyondSpring shares are owned by institutional investors. Comparatively, 66.3% of Minerva Neurosciences shares are owned by institutional investors. 12.0% of Minerva Neurosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Risk and Volatility

BeyondSpring has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500. Comparatively, Minerva Neurosciences has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and target prices for BeyondSpring and Minerva Neurosciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BeyondSpring00403.00
Minerva Neurosciences02302.60

BeyondSpring presently has a consensus target price of $32.6667, suggesting a potential upside of 147.85%. Minerva Neurosciences has a consensus target price of $6.75, suggesting a potential upside of 113.61%. Given BeyondSpring's stronger consensus rating and higher possible upside, research analysts plainly believe BeyondSpring is more favorable than Minerva Neurosciences.

Summary

Minerva Neurosciences beats BeyondSpring on 6 of the 11 factors compared between the two stocks.

Magenta Therapeutics (NASDAQ:MGTA) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, analyst recommendations and earnings.

Earnings & Valuation

This table compares Magenta Therapeutics and Minerva Neurosciences' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Magenta TherapeuticsN/AN/A$-76,770,000.00($2.07)-5.32
Minerva NeurosciencesN/AN/A$-72,180,000.00($1.85)-1.70

Magenta Therapeutics is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Magenta Therapeutics and Minerva Neurosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Magenta TherapeuticsN/A-53.42%-47.67%
Minerva NeurosciencesN/A-51.19%-29.75%

Analyst Ratings

This is a summary of recent ratings and price targets for Magenta Therapeutics and Minerva Neurosciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Magenta Therapeutics00403.00
Minerva Neurosciences02302.60

Magenta Therapeutics presently has a consensus target price of $17.6667, suggesting a potential upside of 60.61%. Minerva Neurosciences has a consensus target price of $6.75, suggesting a potential upside of 113.61%. Given Minerva Neurosciences' higher possible upside, analysts clearly believe Minerva Neurosciences is more favorable than Magenta Therapeutics.

Institutional & Insider Ownership

59.3% of Magenta Therapeutics shares are owned by institutional investors. Comparatively, 66.3% of Minerva Neurosciences shares are owned by institutional investors. 10.9% of Magenta Therapeutics shares are owned by insiders. Comparatively, 12.0% of Minerva Neurosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Risk & Volatility

Magenta Therapeutics has a beta of 2.46, suggesting that its stock price is 146% more volatile than the S&P 500. Comparatively, Minerva Neurosciences has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500.

Summary

Minerva Neurosciences beats Magenta Therapeutics on 7 of the 11 factors compared between the two stocks.

Minerva Neurosciences (NASDAQ:NERV) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, dividends, earnings and profitability.

Valuation and Earnings

This table compares Minerva Neurosciences and Neoleukin Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Minerva NeurosciencesN/AN/A$-72,180,000.00($1.85)-1.70
Neoleukin Therapeutics$25 million20.48$-69,440,000.00($0.75)-16.28

Neoleukin Therapeutics has higher revenue and earnings than Minerva Neurosciences. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Minerva Neurosciences and Neoleukin Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Minerva NeurosciencesN/A-51.19%-29.75%
Neoleukin TherapeuticsN/A-24.06%-21.92%

Analyst Ratings

This is a breakdown of recent ratings for Minerva Neurosciences and Neoleukin Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Minerva Neurosciences02302.60
Neoleukin Therapeutics00703.00

Minerva Neurosciences currently has a consensus price target of $6.75, suggesting a potential upside of 113.61%. Neoleukin Therapeutics has a consensus price target of $22.00, suggesting a potential upside of 79.59%. Given Minerva Neurosciences' higher possible upside, analysts plainly believe Minerva Neurosciences is more favorable than Neoleukin Therapeutics.

Institutional & Insider Ownership

66.3% of Minerva Neurosciences shares are held by institutional investors. Comparatively, 65.7% of Neoleukin Therapeutics shares are held by institutional investors. 12.0% of Minerva Neurosciences shares are held by insiders. Comparatively, 7.1% of Neoleukin Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

Minerva Neurosciences has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500. Comparatively, Neoleukin Therapeutics has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500.

Summary

Neoleukin Therapeutics beats Minerva Neurosciences on 7 of the 12 factors compared between the two stocks.


Minerva Neurosciences Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$6.24+4.0%$529.03 million$143.01 million-1.19Earnings Announcement
Analyst Revision
Altimmune logo
ALT
Altimmune
2.1$16.61+4.0%$527.15 million$5.80 million-8.35Earnings Announcement
Analyst Revision
Gap Down
Amryt Pharma logo
AMYT
Amryt Pharma
1.4$14.74+2.2%$527.10 million$58.12 million-17.14Increase in Short Interest
BeyondSpring logo
BYSI
BeyondSpring
1.2$13.23+1.9%$508.06 millionN/A-6.49Gap Down
Magenta Therapeutics logo
MGTA
Magenta Therapeutics
1.3$11.02+4.6%$507.69 millionN/A-5.65Upcoming Earnings
Gap Down
Neoleukin Therapeutics logo
NLTX
Neoleukin Therapeutics
1.4$12.21+1.4%$504.90 million$25 million-18.78
Crinetics Pharmaceuticals logo
CRNX
Crinetics Pharmaceuticals
1.6$15.73+2.8%$503.38 million$1.19 million-6.55Upcoming Earnings
Affimed logo
AFMD
Affimed
1.6$5.98+5.2%$500.81 million$23.96 million-10.14Gap Down
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.60+4.7%$500.51 million$109.33 million-2.65Gap Down
Akebia Therapeutics logo
AKBA
Akebia Therapeutics
1.6$3.34+3.6%$500.11 million$335 million-1.13Earnings Announcement
Analyst Revision
Viking Therapeutics logo
VKTX
Viking Therapeutics
1.6$7.00+3.7%$499.66 millionN/A-14.29Gap Up
Spero Therapeutics logo
SPRO
Spero Therapeutics
1.5$18.90+3.9%$493.99 million$18.15 million-4.45Gap Down
SIGA
SIGA Technologies
0.3$6.50+2.8%$489.17 million$26.74 million16.25Upcoming Earnings
89bio logo
ETNB
89bio
1.6$24.73+0.7%$488.23 millionN/A-4.90
Homology Medicines logo
FIXX
Homology Medicines
1.7$11.27+4.7%$486.14 million$1.67 million-4.13Gap Down
Spruce Biosciences logo
SPRB
Spruce Biosciences
1.5$22.33+6.4%$485.17 millionN/A0.00Upcoming Earnings
Gap Down
Aldeyra Therapeutics logo
ALDX
Aldeyra Therapeutics
1.8$12.11+1.2%$475.93 millionN/A-9.39
Mirum Pharmaceuticals logo
MIRM
Mirum Pharmaceuticals
1.9$18.43+0.4%$472.16 millionN/A-5.36
Syros Pharmaceuticals logo
SYRS
Syros Pharmaceuticals
1.3$9.40+10.6%$472.06 million$1.98 million-5.66Upcoming Earnings
Gap Down
Avadel Pharmaceuticals logo
AVDL
Avadel Pharmaceuticals
1.3$8.21+2.1%$468.52 million$59.22 million41.05Unusual Options Activity
Gap Down
Inozyme Pharma logo
INZY
Inozyme Pharma
1.7$20.06+0.3%$467.46 millionN/A0.00Upcoming Earnings
Increase in Short Interest
Gap Down
Marinus Pharmaceuticals logo
MRNS
Marinus Pharmaceuticals
1.7$15.86+4.7%$462.28 millionN/A-4.57Gap Down
Wave Life Sciences logo
WVE
Wave Life Sciences
1.8$10.06+6.5%$459.00 million$15.98 million-1.78Upcoming Earnings
Selecta Biosciences logo
SELB
Selecta Biosciences
1.6$4.42+4.5%$455.89 million$6.68 million-5.33
TherapeuticsMD logo
TXMD
TherapeuticsMD
1.5$1.49+2.4%$455.64 million$49.65 million-2.09Upcoming Earnings
Gap Down
DURECT logo
DRRX
DURECT
1.4$2.21+0.5%$451.06 million$29.56 million-44.19Upcoming Earnings
BIVI
BioVie
1.7$25.37+26.5%$446.70 millionN/A0.00Increase in Short Interest
RAPT Therapeutics logo
RAPT
RAPT Therapeutics
1.6$18.78+3.4%$445.67 millionN/A-7.39Gap Down
BioDelivery Sciences International logo
BDSI
BioDelivery Sciences International
2.2$4.28+1.9%$424.67 million$111.39 million30.57
Orphazyme A/S logo
ORPH
Orphazyme A/S
1.5$12.24+1.4%$424.25 millionN/A0.00Increase in Short Interest
News Coverage
Gap Up
MEI Pharma logo
MEIP
MEI Pharma
1.7$3.82+1.8%$421.98 million$28.91 million-6.37Gap Down
Graybug Vision logo
GRAY
Graybug Vision
2.0$19.56+2.7%$421.26 millionN/A0.00Upcoming Earnings
Increase in Short Interest
Immunome logo
IMNM
Immunome
1.1$41.26+4.1%$417.25 millionN/A0.00Upcoming Earnings
Increase in Short Interest
Kala Pharmaceuticals logo
KALA
Kala Pharmaceuticals
1.7$7.39+0.3%$415.52 million$6.07 million-3.54Earnings Announcement
Gap Down
Cue Biopharma logo
CUE
Cue Biopharma
1.3$13.20+3.1%$412.08 million$3.46 million-8.41
Fulcrum Therapeutics logo
FULC
Fulcrum Therapeutics
1.5$13.29+5.1%$411.93 millionN/A-4.61Upcoming Earnings
Gap Down
Evolus logo
EOLS
Evolus
1.1$12.54+3.4%$408.70 million$34.92 million-6.18Upcoming Earnings
Analyst Report
Analyst Revision
Gap Down
Athersys logo
ATHX
Athersys
1.3$2.15+5.1%$403.31 million$5.63 million-5.81
Catalyst Pharmaceuticals logo
CPRX
Catalyst Pharmaceuticals
1.7$4.00+2.8%$403.19 million$102.31 million5.97Gap Down
XOMA logo
XOMA
XOMA
1.6$37.19+2.7%$399.00 million$18.37 million-33.50Decrease in Short Interest
Gap Down
Verastem logo
VSTM
Verastem
1.8$2.44+3.7%$398.97 million$17.46 million-1.73Gap Down
UroGen Pharma logo
URGN
UroGen Pharma
1.9$20.34+6.3%$398.09 million$20,000.00-3.18Gap Down
Puma Biotechnology logo
PBYI
Puma Biotechnology
1.4$10.37+4.0%$396.03 million$272.30 million-7.25Earnings Announcement
Gap Down
RedHill Biopharma logo
RDHL
RedHill Biopharma
1.4$9.24+2.8%$395.08 million$6.29 million-5.31Upcoming Earnings
Analyst Upgrade
Tonix Pharmaceuticals logo
TNXP
Tonix Pharmaceuticals
1.4$1.24+3.6%$385.46 millionN/A-0.35Increase in Short Interest
Gap Down
VYNE Therapeutics logo
VYNE
VYNE Therapeutics
1.8$7.50+0.5%$382.90 million$10.64 million-2.00Upcoming Earnings
Gap Down
Forte Biosciences logo
FBRX
Forte Biosciences
1.6$29.89+4.7%$365.56 million$40,000.00-1.30
CytomX Therapeutics logo
CTMX
CytomX Therapeutics
1.6$8.42+6.8%$362.86 million$57.49 million-7.08Earnings Announcement
Analyst Revision
Gap Down
Nabriva Therapeutics logo
NBRV
Nabriva Therapeutics
1.3$1.86+28.5%$360.38 million$9.48 million-0.32Increase in Short Interest
ANI Pharmaceuticals logo
ANIP
ANI Pharmaceuticals
1.7$29.95+2.8%$359.62 million$206.55 million-15.05
This page was last updated on 3/1/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.